A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Safety and Efficacy of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Safety and Efficacy of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Sirukumab (Primary)
  • Indications Lupus nephritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top